Davis Capital Management Genetic Technologies LTD Transaction History

Davis Capital Management

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Feb 14, 2024	SELL	$0.56 - $3.12 $560 - $3,120	-1,000 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$0.0 - $0.0 $0 - $0	1,000 New	1,000 $0

Ticker GENE
Exchange OTC
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 15,389,900
Market Cap $21.1M
Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...

Get notified when there are updates to the investment portfolio of Davis Capital Management, based on Form 13F filings with the SEC.

Stay updated on Davis Capital Management with notifications on news.